VORANIGO (vorasidenib)

TherapyServier Pharmaceuticals

VORANIGO (vorasidenib) from Servier is a therapy for IDH-mutant low-grade glioma.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and VORANIGO. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where VORANIGO is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Astrocytoma and Oligodendroglioma Solid Tumor · Brain	IDH1 IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for VORANIGO.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering VORANIGO for eligible patients.

Test

Oncomine Dx Target Test

Life Technologies Corporation (ThermoFisher Scientific)

Method

NGS

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to VORANIGO (vorasidenib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.